Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Editorial introduction

Editorial introduction URRENT PINION Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editor for this issue. SECTION EDITOR protection. More recently, his lab was also attracted to the generation of novel antibiotics, a new field of Ralf Wagner increasing clinical importance. He was and is PI and Board Member of several national and international research clusters, such as the EU 7th framework and Ralf Wagner, PhD, is University H2020 program, BMGF (Bill and Melinda Gates Professor for Molecular Micro- Foundation), IAVI (International Aids Vaccine biology (Virology) at the Institute Initiative), NIH (National Institutes of Health), of Medical Microbiology and BMBF (German Ministry of Education and Research, Hygiene, University of Regens- DFG (German Research Foundation), and the Bavar- burg, Germany. Dr Wagner gradu- ian Research Foundation. Dr Wagner is actively ated at the Ludwig-Maximilians- engaged in teaching programs, is inventor and co- University (LMU) in Munich, inventor of several patents and patent applications, one of the Elite Universities in and is author of numerous scientific peer reviewed Germany. He earned his PhD at publications. Furthermore, he also acts as reviewer the Max-von-Pettenkofer Institute (LMU), where he for various national and international funding had already started to work on HIV with a focus on organisations. virion morphogenesis. Following training as PostDoc Besides his academic activities Dr Wagner was at the Institute of Medical Microbiology and Hygiene Founder, CEO and Chief Scientific Officer (2000 – at the University of Regensburg, he received his post- 2012) of GeneArt AG, a previously public biotech company and now part of Thermofisher Inc. with doctoral lecture qualification in Medical Micro- more than 300 employees working at the GeneArt biology and built a team of young scientists concentrating on HIV vaccine development. He site in Regensburg, Germany. He was amongst the was appointed Professor for Molecular Microbiology first scientists to recognize the value of gene to (Virology) at the same Institute in 2003. genome design and synthesis for different areas Since then, Dr Wagner has been involved in of biotechnology, including metabolic pathway many different aspects of vaccine research including engineering and the development of novel antimi- studies on HIV molecular epidemiology, and patho- crobial compounds, as well as immunogen and genesis and replication, as well as the development vector design for vaccination or gene therapy pur- of non-viral and viral vector systems and immuno- poses, and thus consequently translated basic gens for their validation in preclinical and clinical research tools into scalable technologies and new studies. He pioneered the utilization of recombinant products. Together with his company, he received HI-virus like particles for vaccine delivery and various awards including the European Biotech broadly established the concept of RNA and codon Award (Biotechnica Europe). After the acquisition optimization for recombinant vaccine develop- by Life Technologies Inc., he successfully coordi- ment. Several immunogens which were conceptu- nated the integration process and served within the alized in his lab and validated together with partners US Corporation as Vice President of Synthetic from academia and industry reached phase 1 and 2 Biology. Today, he is Board Member of several bio- clinical trials, showed excellent safety profiles and tech companies and local venture capital funds and induced immune responses supposed to correlate supports University derived spin-offs as business with control of HIV replication and possibly coach. 1746-630X Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved. www.co-hivandaids.com Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Editorial introduction

Wagner, Ralf
Current Opinion in HIV and Aids , Volume 12 (3) – May 1, 2017
Download PDF
1 page

Loading next page...
 
/lp/wolters-kluwer-health/editorial-introduction-6gBvnsgky5

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000373
Publisher site
See Article on Publisher Site

Abstract

URRENT PINION Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editor for this issue. SECTION EDITOR protection. More recently, his lab was also attracted to the generation of novel antibiotics, a new field of Ralf Wagner increasing clinical importance. He was and is PI and Board Member of several national and international research clusters, such as the EU 7th framework and Ralf Wagner, PhD, is University H2020 program, BMGF (Bill and Melinda Gates Professor for Molecular Micro- Foundation), IAVI (International Aids Vaccine biology (Virology) at the Institute Initiative), NIH (National Institutes of Health), of Medical Microbiology and BMBF (German Ministry of Education and Research, Hygiene, University of Regens- DFG (German Research Foundation), and the Bavar- burg, Germany. Dr Wagner gradu- ian Research Foundation. Dr Wagner is actively ated at the Ludwig-Maximilians- engaged in teaching programs, is inventor and co- University (LMU) in Munich, inventor of several patents and patent applications, one of the Elite Universities in and is author of numerous scientific peer reviewed Germany. He earned his PhD at publications. Furthermore, he also acts as reviewer the Max-von-Pettenkofer Institute (LMU), where he for various national and international funding had already started to work on HIV with a focus on organisations. virion morphogenesis. Following training as PostDoc Besides his academic activities Dr Wagner was at the Institute of Medical Microbiology and Hygiene Founder, CEO and Chief Scientific Officer (2000 – at the University of Regensburg, he received his post- 2012) of GeneArt AG, a previously public biotech company and now part of Thermofisher Inc. with doctoral lecture qualification in Medical Micro- more than 300 employees working at the GeneArt biology and built a team of young scientists concentrating on HIV vaccine development. He site in Regensburg, Germany. He was amongst the was appointed Professor for Molecular Microbiology first scientists to recognize the value of gene to (Virology) at the same Institute in 2003. genome design and synthesis for different areas Since then, Dr Wagner has been involved in of biotechnology, including metabolic pathway many different aspects of vaccine research including engineering and the development of novel antimi- studies on HIV molecular epidemiology, and patho- crobial compounds, as well as immunogen and genesis and replication, as well as the development vector design for vaccination or gene therapy pur- of non-viral and viral vector systems and immuno- poses, and thus consequently translated basic gens for their validation in preclinical and clinical research tools into scalable technologies and new studies. He pioneered the utilization of recombinant products. Together with his company, he received HI-virus like particles for vaccine delivery and various awards including the European Biotech broadly established the concept of RNA and codon Award (Biotechnica Europe). After the acquisition optimization for recombinant vaccine develop- by Life Technologies Inc., he successfully coordi- ment. Several immunogens which were conceptu- nated the integration process and served within the alized in his lab and validated together with partners US Corporation as Vice President of Synthetic from academia and industry reached phase 1 and 2 Biology. Today, he is Board Member of several bio- clinical trials, showed excellent safety profiles and tech companies and local venture capital funds and induced immune responses supposed to correlate supports University derived spin-offs as business with control of HIV replication and possibly coach. 1746-630X Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved. www.co-hivandaids.com Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: May 1, 2017

There are no references for this article.